Kezar Life Sciences Inc (KZR)

KZR at one time had the best data for LN , then ran into some unexpected adverse events IIRC .
Dont own either AUPH or KZR but still have my position in KOD plus others

Kiwi

Kezar Life Sciences shares surge after Aurinia announces acquisitionMarch 30, 2026 11:07 AM
IH Market News
Kezar Life Sciences Inc. (NASDAQ:KZR) shares jumped about 19% on Monday after Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced an agreement to acquire the company for $6.955 per share in cash plus a contingent value right (CVR).Under the terms of the deal, the CVR could provide additional payments tied to the clinical development or potential sale of Kezar’s lead drug candidate zetomipzomib. The CVR may also include proceeds related to Kezar’s collaboration with Everest Medicines, the sale of its Sec61-based program to Enodia Therapeutics, and 100% of Kezar’s closing net cash above $50 million, after certain CVR-related expenses.Zetomipzomib is Kezar’s lead asset and is described as a first-in-class immunoproteasome inhibitor currently being developed to treat autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The drug demonstrated durable, clinically meaningful steroid-sparing remissions in patients during the PORTOLA Phase 2 study in autoimmune hepatitis. Kezar also reported positive discussions with the U.S. Food and Drug Administration during a recent Type C meeting regarding the drug’s development pathway in AIH.Kezar’s board of directors unanimously approved the acquisition following a strategic review conducted with management and external advisors.Aurinia plans to launch a tender offer by April 13, 2026, to purchase all outstanding shares of Kezar. Completion of the transaction will depend on several conditions, including the tender of a majority of Kezar’s outstanding shares, the company maintaining more than $50 million in closing net cash, and other customary closing requirements.Tang Capital Partners, which owns approximately 9% of Kezar’s outstanding shares, has signed a tender and support agreement committing to tender its holdings and back the transaction.The acquisition is expected to close in the second quarter of 2026. TD Cowen served as Kezar’s exclusive financial advisor, while Cooley LLP acted as legal counsel for the company.Kezar Life Sciences stock priceAurinia Pharmaceuticals stock price

Original: Kezar Life Sciences shares surge after Aurinia announces acquisition

So the old adage, if you don't succeed, try, try again. Tang now as CEO of AUPH buys Kezar.

$KZR: Thats an offering................

Yikes............... they shot themselves in the foot.

I dunno....... depends on what they are setting up for.

I mean, $MLGO did an $0.80 offering today, shoulda gone down but shot up ........ WAY up.

Very contrary to what it shoulda done.

I don't know what to tell you........ don't have a good handle on $WLGS

Hey............... gimme a FREE annual iHUB full on sub............. maybe i'll have the tools to make a better decision.

GO $KZR

WLGS -86% Chiner ... Buy ? or Ignore ? Mr. Makezmy

$KZR: Topline Ph.2 tomorrow...................

Hmmmmmmmmmmmmm.................. should I get some $10 4/17 calls ???

I hear rumblings.

Will decide before end of Day


GO $KZR

KZR...........................https://stockcharts.com/h-sc/ui?s=KZR&p=W&b=5&g=0&id=p86431144783

$KZR Tang with a non-binding proposal to acquire 100% of the equity of Kezar Life Sciences, Inc. for $1.10 per share in cash, plus a CVR

https://archive.fast-edgar.com/20241008/ABBOQ22CIC22L2ZZ282R2MZZL8LQZ2Z2Z262/

Kiwi

Pump it $$$$$

It will be over $3 soon…..I just my annual meeting notice…..they are looking at and voting on to reverse split the stock

$KZR valuation $3++ based on market cap of $271mil and HUNDREDS of millions of cash on hand, puts thos over $3++ #LFG

KZR under $2

As an update . After doing more research into NVS's Cosentyx and their P 3 trial a week or so ago .....I sold most of my KZR position ...retaining only 100 shares..
I liked the KZR data but now realize that if the Cosentyx LN trial succeeds ( primary completion Jan 2025 ) , they will file for accelerated approval and dominate the non generic drug portion of this market.
The lesson from this .
Know the competition and don't fall in love with a stock
Kiwi

Yahoo finance today reporting market cap at $271.2 m
Cash on hand from EOY financial statement
Cash, cash equivalents and marketable securities totaled $276.6 million as of December 31, 2022

Kiwi

Well I obviously should have waited until after watching their presentation
Two trials that wont read out to 2025 . The LN trial is large and will compete with other large LN trials being run by NVS for enrolling patients .
Co now trading for cash on hand .
I still believe in their drug but acknowledge that this is a very high risk investment as there is real concern the the LN trial in particular will take longer , cost more and that they'll need more $ .
I added some to lower my cost below $5 .
Very small position that I'll set aside and see if it evaporates :--)
Writing this mainly as a note to myself as no one reads this board
Kiwi

Buying at these levels . Their LN program looks to be kicking into gear . Update on Wed.
. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details," said John Fowler, Kezar’s Co-founder and Chief Executive Office
Kiwi

For the record ...not that anyone reads this board anyway
I reduced my position in KZR following their JPM run up boost.
What I liked about their data was that there was no induction period before starting the drug and the data was in refractory patients . The JPM presentation indicated to me at the time that they were slower then I expected progressing into a P 3 trial .
If U want more data suggest U chk their JPM slide deck.

I now actual question if they'll commit to a large P 3 until they see the Secukinumab trial results ( Cosentyx )...trial ends in Jan 2025 I think. There may be an interim readout before hand .
Cosentyx is an already approved drug and NVS ( ? ) appears to be committing a lot of $ to try and get it approved for LN.
Good luck

Kiwi

So the first full trading day after KZR and AUPH presented at JPM

KZR up 12.4% on double normal vol. Consistent buying with large buys towards close . Up 2.9% after hrs
AUPH up 5.2% on average vol. Large sale mid day . Little after hrs

Risk to KZR is they still have to run a pivotal trial that shows better data than AUPH's pivotal trial .
Risk to AUPH is the much hyped buyout doesn't materialize and the Co slowly burns thru its cash on hand trying to breakeven .

Kiwi

https://finance.yahoo.com/news/kezar-life-sciences-presents-positive-140000967.html

On first glance data looks better then Benlysta or Lupkynis .
Lupkynis is way over priced with a limited market ...Benlysta may be going generic soon ( altho still expected to be expensive )
Kiwi

HC Wainwright & Co. Maintains Buy on Kezar Life Sciences, Raises Price Target to $21

Kiwi

Kezar is reporting an unaudited cash position of approximately $307 million, including cash, cash equivalents and marketable securities as of June 30, 2022.

No need for funding any time soon ...and they hired a new business development guy with a background in deals / partnerships

Kiwi

I covered the other day at $7.75. Just when I saw it over $11+ premarket I knew there would be downside.

Take care W!

Well sell the news … something I usually do but not in this case
Are U still short ?

Nephrologist my wife works with likes the data
Early days etc etc but potential to protect kidneys without or limited steroid use … is what he liked

Kiwi

Shorted 1,500 at $11.20 premarket, still holding for $6-$7s tomorrow.

Boy what timing on buying 2m more shares


Inquiring minds Would like to know what he knew

It was a P 2 trial and there was no mandate to lower steroid use....altho some did anyway .
Remember this was largely a refractory population , there was no induction therapy and eGFR remained stable from baseline to end of trial .

Re drop outs ..this trial was being run during the worst of the Omicron surge . Patients needed to come to the clinic for their weekly sub Q injection .Hospital visits for all procedures were down as patients avoided hospitals if they could.

The P 3 trial ( or trials ) will be in a larger more diverse LN population ...maybe 2 trials ...one with induction therapy the other not and where reducing steroid use will be mandated

Just my take
Kiwi

Congratulations KZR on their phase 1B open label, single arm, 29 week study! But are you sure it wasn't the steroids? 9 mg/day at completion.

Also, what happened to the 4 patients (20% of total population) who dropped out? And who, by the way, were excluded from the data presented.

CEO still under water on his big buy, even after this move

https://www.bizjournals.com/sanfrancisco/news/2022/06/27/lupus-nephritis-kezar-kzr-zetomipzomib.html?taid=62ba5bf308e7840001dcc906&utm_campaign=trueAnthem%3A+New+Content+%28Feed%29&utm_medium=trueAnthem&utm_source=twitter

Kiwi

New position disclosed in KZR...Israel Englander


And now we can understand Englander’s position on the stock. The billionaire investor held just over 922K shares at the end of Q1 – but this past June 17, he reported overall holdings of 3,026,628 shares. This was more than triple his previous disclosure, and gives him a 5% stake in Kezar. At current values, Englander’s holdings in KZR are worth more than $17.4 million.

Kiwi

Kezar Life Sciences (KZR)...from TipRanks

We’ll wrap up with a clinical-stage bioscience researcher, Kezar Life Sciences. This company is involved in the fields of oncology and immunology, and is developing new treatments for cancers and autoimmune diseases. The company’s pipeline features first-in-class small molecule drug therapies with activity in protein degradation and protein secretion.

Kezar’s pipeline features two clinical-stage drug candidates, KZR-261 and KZR-616. The first of these has recently advanced from the discover stage and the company has initiated a Phase 1 open-label dose-escalation study. The drug candidate is being studies as a potential treatment for solid tumor cancers.

The real excitement for this company comes from the two Phase 2 trials of KZR-616. This is an autoimmune drug, under investigation as a treatment for Lupus, among other conditions. The company in December released interim results from its MISSION trial of KZR-616, showing that the drug candidate demonstrated clinically meaningful benefits in patients suffering from Lupus nephritis. The patient pool was small, only 5, but 4 patients showed positive results. In addition, the drug continued to show a ‘favorable’ profile for safety and tolerability, extended over 6 months. Top-line data from the MISSION trial expected in 2Q22.

Kezar also has the PRESIDIO trial ongoing, investigating KZR-616 against active dermatomyositis (DM) or polymyositis (PM). The Phase 2 trial is described as a ‘randomized, placebo-controlled, double-blind, cross-over clinical trial,’ and has enrolled 24 patients. Topline data from PRESIDIO is also expected in the second quarter of this year.

Finally, Kezar has recently announced that it has selected ‘zetomipzomib’ as a brand name for KZR-616.

Kezar also shows a recent ‘million +’ insider trade. Franklin Berger, of the company’s Board, made a purchase worth $1.299 million earlier this week. His buy totaled 80,000 shares, and it brought his stake in Kezar up to an impressive $14.28 million.

This stock has attracted the notice of H.C. Wainwright analyst Raghuram Selvaraju, who points out that the multiple upcoming catalysts are a strong inducement for investors. Selvaraju writes, “In our view, positive data for zetomipzomib from both the MISSION and PRESIDIO trials ought to establish Kezar as a triple-threat across SLE/LN, DM and PM and position the compound for advancement into late-stage clinical development. Depending upon the strength of the data, Kezar might also ultimately be considered an attractive potential acquisition target, in our opinion.”

Large open market purchase by a director

http://archive.fast-edgar.com/20220322/AIZIS22C3M22GJK222222ZZ29DCUZ22S4242/

Kiwi

Still think this is a crap stock Ganz ?
New high today
Your pal the Tool
Kiwi

Compare AUPH to KZR in this sell off .
Theres a lot more downside vol in AUPH then in KZR . A lot of retail in AUPH ..a lot of institutions in KZR .
There is a market for AUPH's drug ...just not as large as U think ...meanwhile that Co will burn thru their cash trying to build script numbers
Kiwi

Buy some AUPH if you want some returns

This is a crap stock

ONLY 2 DRUGS LOSING 60 MILLION A YEAR NO REVENUES INSIDERS ROBBING SHAREHOLDERS BLIND SELL THIS TRASH WARRANTS AT .0001 PER SHARE NOW THEY NEED TO RAISE EVEN MORE MONEY TO BURN AND WHY IN THE HELL DO THEY ONLY HAVE 5 PATIENCES IN A STUDY FOR BLAH

WARRANTS FOR .0001 FOR SHARES YUCK NO REVENUES HUGE LOSSES LOSING OVER 50 MILLION A YEAR BOOK VALUE UNDER 2$ A SHARE AND WILL BE UNDER 1$ SOON AT THE CURRENT BURN RATE STILL NEED TO DO A COMPLETE PHASE 3 STUDY THEY WILL HAVE TO RAISE MORE MONEY TO BURN TO FUND IT AND THESE GUYS DONT CARE TO HAND OUT STOCK LIKE ITS CANDY BASICALLY FOR FREE AS THE LAST STOCK OFFERING CLEARLY SHOWED EVERY SINGLE BUYER IS A BAGHOLDER LOSER TODAY

KZR - Monday Rundown, Tuesday Expectations

over 3,000 OTM calls with expiry this Friday purchased today before news released. That looks really fishy.

* * $KZR Video Chart 06-04-2020 * *

Link to Video - click here to watch the technical chart video

What can you tell me about this company?

Opening up this morning.

Not wasting any time with a slow opening or a head fake down. This is the real deal.

Up in AH. Good opening tomorrow.

Slow and steady wins the race.

This is insane today.

Only have 1K shares, wish I had 10K shares. This could continue going up quite a bit from there. Thew NEWS today was great.

Nice move today.

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.